Bridgewater Chapter Upcoming Events Join PCCI

Enantigen Therapeutics Inc.

A pharmaceutical company

Presenter: Michael Xu, PhD, President and COO of Enantigen


Monday, January 14, 2013

Embassy Suites, Chesterbrook, Pennsylvania (directions)




Enantigen Therapeutics, Inc. is an innovative pharmaceutical company located at the Pennsylvania Biotechnology Center and striving for excellence in the discovery, development and commercialization of novel drugs to treat life-threatening infectious diseases. The primary focus is on the development of oral therapeutics for the treatment of hepatitis B.


Currently there is no definite cure for chronic HBV infection. Interferon-alpha products and nucleosides analogs have been approved for the treatment of HBV. The latter have become the mainstay of treatment owing to their oral administration and better side-effect profile. However, the emergence of viral resistance has been a challenge. Although the pathogenicity of polymerase inhibitor resistant mutants is uncertain, there clearly remains a need for alternatives and complements to interferon and nucleoside analogs, and for a diversity of approaches in developing HBV therapy.


Enantigen’s key interest and expertise is in chronic viral hepatitis. They are advancing compounds with activity against novel hepatitis B targets derived through novel screening methodologies (potentially curative) for the treatment of chronic hepatitis B virus infection. New families of drugs with novel modes of action would have enormous clinical value. New classes of agents, as  are being developed, used alone or in combination with existing agents, would be anticipated to increase cure rates and would allow for the treatment of HBV carriers much earlier in the course of the disease.



3 Major Issues


  1. Assuming Enantigen will seek an estimated $20 million to advance their two projects through successful Phase II human clinical trials, how should management structure the raise and prioritize development in order to maximize the company's valuation?
  2. What should Enantigen look for in a BD person or a CEO? And how should the company structure his/her compensation?
  3. Hepatitis B is very prevalent in China. There are potential Chinese investors who showed interest in Enantigen's compounds. They have suggested formation of a joint VC in China. What are the pro's and cons of entering into a strategic partnership with a Chinese company?




6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)

8:00 - Michael Xu, PhD, President and COO of Enantigen, will deliver the Company's "Elevator" Pitch to the Group

8:20 - A Panel will address 3 Major Issues for the Company

9:00 - Open discussion: members and guests



<Top of the page>




Available Media

Please note: All information obtained here is the property of those presenting and should not be copied or duplicated without written consent.



None available at this time


None available at this time


None available at this time


Enantigen Webcast - 01/14/13

Contact Info:




Our Sponsors


EisnerAmperIdeas x Innovation Network i2nNew Jersey Institute of TechnologyScience Center


<Top of the page>





Questions or Coments?

Contact: Peter van der Kam, | (610) 296-8086




Good Company! Good Drink! Good Food! Good Program! Good Fun!


Site Navigation



Pharmaceutical Consulting Consortium International, Inc., or (610) 296-8086

Meetings Held at Embassy Suites - Valley Forge

888 Chesterbrook Blvd, Chesterbrook, Pennsylvania 19087

All content on this website is copyrighted and should not be reproduced without the consent of PCCI.

© Copyright 2016-2018



Tat Communication Inc